Food and Drug
Administration
Cardiovascular and Renal Drugs Advisory Committee
Hilton Washington DC
North/Gaithersburg
Gaithersburg Maryland
SLIDES
April 26, 2006
8:00
A.M. – 12:00 P.M.
The committee will discuss the agency’s draft recommendations
for relabeling of antihypertensive drugs for outcome claims,
as a follow-up to the committee’s meeting on June 15, 2005,
where the committee discussed class labeling of antihypertensive
drugs based on the proximity of their data to outcome trials
OPEN
PUBLIC HEARING SPEAKERS
Merrill Goozner, Center for Science in
the Public Interest, Washington,
DC (pdf)
William R. Hiatt, M.D. (No formal written presentation
provided)
John M. Flack, M.D., M.P.H. (No formal written presentation
provided)
Up
| AC Home Page